Mizuho on Terns Pharmaceuticals (TERN): MRK acquisition 'makes sense on multiple levels'

March 25, 2026 10:18 AM

Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $54.00 price target on Terns Pharmaceuticals (NASDAQ: TERN)The analyst commented, "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found